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eTATE-OF-THE-ART PAPER1013The Role of the Immune System in HFames E. Fildes, Steven M. Shaw, Nizar Yonan, Simon G. Williams
everal lines of evidence, including the link between elevated cytokine levels and poor
utcomes, suggest an important role of the immune system in the propagation of heart failure
HF). However, attempts with various immunomodulatory therapies have been largely
nsuccessful to date. Fildes and colleagues propose that this failure is because the immune
esponse in HF is a secondary phenomenon in response to myocyte injury, rather than a
rimary abnormality. Therapies that suppress the myocyte stress signals that trigger the
mmune response are likely to be more successful than strategies that seek to modify the
mmune response.CLINICAL RESEARCH CUTE CORONARY SYNDROMES1021Reduced Risk of Bleeding With Bivalirudin in Elderly ACS Patients CMEenato D. Lopes, Karen P. Alexander, Steven V. Manoukian, Michel E. Bertrand, Frederick Feit,
arvey D. White, Charles V. Pollack, Jr, James Hoekstra, Bernard J. Gersh, Gregg W. Stone,
. Magnus Ohman
opes and colleagues performed a subgroup analysis of the ACUITY (Acute Catheterization
nd Urgent Intervention Triage Strategy) trial to determine if patient age modified the results
een in the larger trial. The ACUITY trial randomized patients with moderate- and high-risk
cute coronary syndromes (ACS) to either bivalirudin or a heparin plus a glycoprotein IIb/
IIa inhibitor. Eighteen percent of the subjects were 75 years of age; these subjects had
imilar ischemic outcomes with either therapy but significantly lower rates of bleeding when
reated with bivalirudin. The number needed to treat with bivalirudin to avoid 1 major bleed
as only 23 in subjects age 75 years, compared to 67 in those age 55 years. Patients over
ge 75 years are at increased risk of both ischemic and bleeding complications compared with
ther ACS patients; bivalirudin appears to provide similar efficacy with improved safety,
specially in elderly patients.(continued on page A-20)
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rNTERVENTIONAL CARDIOLOGY1031Specialized Bifurcation Stent Shows Promising Resultstefan Verheye, Pierfrancesco Agostoni, Christophe L. Dubois, Joseph Dens, John Ormiston,
tephen Worthley, Brett Trauthen, Takao Hasegawa, Bon-Kwon Koo, Peter J. Fitzgerald, Roxana Mehran,
lexandra J. Lansky
he Axxess (Devax Inc., Lake Forest, California) self-expanding drug-eluting stent is
pecifically designed for coronary bifurcation lesions. It is designed to deliver full drug
overage to the carina between the branches and the capability to pass subsequent stents into
ither branch. Three hundred patients with bifurcation lesions were enrolled in a multicenter
tudy with clinical and angiographic follow-up at 9 months. The cumulative 9-month major
dverse cardiac event rate was 7.7% (0.7% death, 3.3% non–Q-wave myocardial infarction
MI], 1.0% Q-wave MI, 4.3% target lesion revascularization). This prospective, multicenter
tudy confirms the safety and performance of the Axxess stent in bifurcation lesions with
esults that may be superior to other bifurcation techniques.ONTRAST-INDUCED NEPHROPATHY1040ANP Infusion Reduces the Incidence of Contrast-Induced NephropathyEditorial Commenthuji Morikawa, Takahito Sone, Hideyuki Tsuboi, Hiroaki Mukawa, Itsuro Morishima,
ichitaka Uesugi, Yasuhiro Morita, Yasushi Numaguchi, Kenji Okumura, Toyoaki Murohara
trial natriuretic peptide (ANP) is a potent endogenous diuretic and natriuretic substance
hat has been shown to improve renal function and perfusion in ischemic renal failure.
orikawa and colleagues compared a 48-h infusion of ANP, beginning 4 to 6 h prior to
ngiography, with a hydration-only infusion for the ability to prevent contrast-induced
ephropathy (CIN). The prevalence of CIN, defined as a 25% rise in creatinine or an
ncrease in creatinine of 0.5 mg/dl from baseline, was significantly lower in the ANP group
han in the control group (3.2% vs. 11.7%). ANP infusion appears to be more effective than
imple hydration for preventing CIN in patients scheduled for angiography.ARDIAC RESYNCHRONIZATION THERAPY
10502-Lead Holter May Be Necessary to
Determine the Efficiency of CRT in Patients With AFanesh S. Kamath, Delia Cotiga, Jayanthi N. Koneru, Aysha Arshad, Walter Pierce, Emad F. Aziz,
nisha Mandava, Suneet Mittal, Jonathan S. Steinberg
t is unclear whether patients with chronic atrial fibrillation (AF) derive the same benefit from
ardiac resynchronization therapy (CRT) as those with normal sinus rhythm. Kamath and
olleagues were concerned that device counters may not discriminate between full
iventricular capture and fusion or pseudo-fusion beats. They identified 19 patients with
ermanent AF and a CRT device where device interrogation showed 90% biventricular
BiV) pacing. The 12-lead Holter recording showed that only one-half of the patients had
90% BiV capture while the other one-half had frequent fusion and pseudo-fusion beats.
linical follow-up confirmed that those with true biventricular capture were more likely to
espond favorably to CRT.(continued on page A-21)
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hERIPHERAL VASCULAR DISEASE1056Mildly Reduced ABI Predicts Increased Risk of Loss of MobilityEditorial Commentary M. McDermott, Jack M. Guralnik, Lu Tian, Kiang Liu, Luigi Ferrucci, Yihua Liao, Leena Sharma,
ichael H. Criqui
ersons with peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI)
0.90, have greater functional impairment and faster rates of functional decline than persons
ithout PAD. McDermott and colleagues studied patients with an ABI that was slightly low
0.90 to 1.09) and found that these patients were also more likely to become unable to walk
or 6-min continuously during 5 years of follow-up compared with those with a normal ABI
1.10 to 1.30). A low-normal ABI is associated with an increased incidence of mobility loss
ompared with persons with a normal ABI.ONGENITAL HEART DISEASE1065Hypoplastic Left Heart Syndrome is Genetically Related to Bicuspid Aortic ValveEditorial Comment
Paul Grossfeld, Maoqing Ye,obert B. Hinton, Lisa J. Martin, Smitha Rame-Gowda, Meredith E. Tabangin, Linda H. Cripe,
. Woodrow Benson
amilies of patients with hypoplastic left heart syndrome (HLHS) seem to have higher rates
f bicuspid aortic valve (BAV), suggesting a possible genetic link. Hinton and colleagues
creened family members of patients with either HLHS or BAV with a family-based
enome-wide linkage analysis and screening echocardiograms. The recurrence risk ratio of
AV in HLHS families (8.0) was nearly identical to that in BAV families (8.8). Several
hromosomal regions were identified that may predispose to one or both disorders. These
tudies demonstrate a linkage to multiple chromosomal loci, identifying HLHS as a
enetically heterogeneous disorder that is at least partially related to BAV.PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH1075CRT Can Be Modified to Measure Impedance, Correlates With CHFirar S. Khoury, Mihir Naware, Jeff Siou, Andreas Blomqvist, Nilesh S. Mathuria, Jianwen Wang,
ue-Teh Shih, Sherif F. Nagueh, Dorin Panescu
houry and colleagues used a modified cardiac resynchronization therapy (CRT) device to
easure thoracic impedance in a dog model of pacing-induced congestive heart failure
CHF). The impedance, essentially the drop in voltage, between various system components
as periodically measured and compared with measures of left ventricular (LV) function and
eft atrial (LA) pressure. Impedance decreased significantly in all measured vectors; the
hanges in impedance were highly correlated with both LA pressure and LV end-diastolic
olume. Impedance vectors from CRT devices may be useful for ambulatory monitoring in
eart failure patients.(continued on page A-26)
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dEWS FROM THE NHLBI1084CV Programs of the NHLBIlizabeth G. Nabel, Michael S. Lauer
he National Heart, Lung, and Blood Institute (NHLBI) is committed to expanding
nowledge regarding the pathobiology of cardiovascular (CV), lung, and blood disorders and
ranslating this knowledge into improved clinical outcomes for both individual patients and
he broader public health. The NHLBI’s blueprint for guiding, stimulating, and supporting
utstanding science is articulated in its Strategic Plan: Shaping the Future of Research. In the
oming months, Nabel and Lauer plan to share the NHLBI’s strategic vision and provide
etails of current and developing programs designed to fulfill this vision.
